Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hologic, Inc. - Common Stock (NQ:HOLX)

67.95 -0.81 (-1.17%)
Streaming Delayed Price Updated: 12:18 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hologic, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic’s Patent Rights
From Hologic, Inc.
Via Business Wire
Hologic's Return On Capital Employed Overview
Pulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q3 earnings of $228.40 million, an increase from Q2 of 49.88%. Sales dropped to $1.00 billion, a 30.15% decrease between quarters. 
Via Benzinga
Hologic Announces Financial Results for Third Quarter of Fiscal 2022
From Hologic, Inc.
Via Business Wire
Analyst Ratings for Hologic
Within the last quarter, Hologic (NASDAQ:HOLX) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Hologic
Analysts have provided the following ratings for Hologic (NASDAQ:HOLX) within the last quarter: 
Via Benzinga
Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue
 
Via Benzinga
Expert Ratings for Hologic
Analysts have provided the following ratings for Hologic (NASDAQ:HOLX) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
7 Nasdaq Stocks Trading at a Huge Discount Right Now
With the markets performing worse than they have in years, finding Nasdaq stocks trading at a discount is easier than ever. 
Via InvestorPlace
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2022 on Wednesday, July 27, 2022
From Hologic, Inc.
Via Business Wire
New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options
From Hologic, Inc.
Via Business Wire
Augmented Realty and Virtual Reality in Healthcare Market Size, Share, Trends, Industry Analysis, Growth, Business Plan, Opportunities and Forecast 2022-2028
Global Augmented Realty and Virtual Reality in Healthcare Market Dynamics 2022-2028, Regional Analysis, Segmentation, Competitive Landscape, COVID-19 Impact, Recent Developments and SWOT Analysis of... 
Via SBWire
Medical Imaging Informatics Market New Innovations Trends, Research, Global Share and Growth Factor
Medical Imaging Informatics Market New Innovations Trends, Research, Global Share and Growth Factor According to a new report published by Allied Market Research, titled, The medical imaging... 
Via iCrowdNewswire
Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree
From Hologic, Inc.
Via Business Wire
Laser Hair Removal Service Market Size, Share, Trends & Analysis by Application, Technology, Key Companies, Opportunities and Forecast 2022–2028
Intelligence Market Report Publish New Research Report On-“Laser Hair Removal Service 2022 Market Analysis by Key Players, Applications, Growth Trends, Share & Segment Forecast to 2028” 
Via SBWire
CNBC's Final Trades: Charles Schwab And These 3 Medical Stocks
On CNBC’s “Halftime Report Final Trades,” Karen Firestone of Aureus Asset Management said Charles Schwab Corporation (NYSE: SCHW) is trading at 14 times next year’s earnings. 
Via Benzinga
15 Stocks Moved By Traders on 'Fast Money: Halftime Report'
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The... 
Via Benzinga
Hologic Announces FDA Approval of Aptima® CMV Quant Assay for Human Cytomegalovirus
From Hologic, Inc.
Via Business Wire
Hologic to Webcast Presentation at Upcoming Investor Conference
From Hologic, Inc.
Via Business Wire
Hologic's Return On Capital Employed Overview
Pulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters. 
Via Benzinga
Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know
Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours,... 
Via Benzinga
Hologic Announces Financial Results for Second Quarter of Fiscal 2022
From Hologic, Inc.
Via Business Wire
American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy
From Hologic, Inc.
Via Business Wire
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2022 on Wednesday, April 27, 2022
From Hologic, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022
Upgrades 
Via Benzinga
7 S&P 500 Stocks That Have Raised Their Guidance in 2022
The number of companies raising guidance in 2022 has been slower than usual. Here are seven S&P 500 stocks that have upped guidance. 
Via InvestorPlace
Digital Breast Tomosynthesis Market Size Estimated to Grow at CAGR 13.2% During 2022-2027
Via AB Newswire
Topics Product Recall
Digital Breast Tomosynthesis Market Size Estimated to Grow at CAGR 13.2% During 2022-2027
Continue reading "Digital Breast Tomosynthesis Market Size Estimated to Grow at CAGR 13.2% During 2022-2027" 
Via Get News
Topics Product Recall
Death Cross Looms Over Hologic Investors
If history is any guide, there may be trouble ahead for shares of Hologic (NASDAQ:HOLX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.